Blincyto

Approved Uses

Blincyto is used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). This is a fast-growing cancer where the bone marrow produces too many immature white blood cells. It is specifically indicated for use in the following situations:

• Relapsed or Refractory ALL: For patients whose cancer has returned after previous treatment or did not respond to initial therapies.
• Minimal Residual Disease (MRD): For patients who are in remission but still have a small, detectable amount of cancer cells (minimal residual disease) remaining in the body.
• Consolidation Therapy: As a part of the consolidation phase of treatment for patients with Philadelphia chromosome-negative B-cell precursor ALL to help maintain remission.

This medication is approved for use in both adult and pediatric patients. It is typically used when the leukemia cells have a specific protein on their surface called CD19.

Mechanism of Action

Blincyto belongs to a class of drugs known as bispecific T-cell engagers (BiTE). It is designed to treat certain types of B-cell precursor acute lymphoblastic leukemia (ALL) by helping the body's immune system identify and attack cancer cells.

The medication works by targeting two specific proteins simultaneously:

• CD19: This protein is found on the surface of B-cell leukemia cells.
• CD3: This protein is found on the surface of T cells, which are white blood cells that help the immune system fight disease.

By binding to both CD19 and CD3, Blincyto acts as a bridge that brings the T cells into direct contact with the leukemia cells. This proximity triggers the T cells to become active and release substances that cause the cancer cells to break down and die. This process allows the immune system to specifically target the cancer cells while minimizing the impact on other healthy cells that do not carry the CD19 protein.

Common Side Effects

Many people using Blincyto experience mild to moderate side effects. These may include:

• Fever and chills
• Headache
• Infections
• Nausea, vomiting, diarrhea, or constipation
• Swelling in the hands, ankles, or feet
• Skin rash
• Fatigue or feeling very weak
• Tremors or shaking
• Low blood cell counts

Serious Side Effects

Blincyto can cause serious or life-threatening reactions. Contact a healthcare provider immediately if you experience any of the following:

• Neurological problems: This may include confusion, seizures, difficulty speaking or slurred speech, loss of balance, or loss of consciousness.
• Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever, low blood pressure, and trouble breathing.
• Liver toxicity: Symptoms may include yellowing of the skin or eyes, dark urine, or pain in the upper right stomach area.
• Pancreatitis: Severe pain in the upper stomach that may spread to the back, often accompanied by nausea and vomiting.
• Tumor Lysis Syndrome: Caused by the rapid breakdown of cancer cells, which can lead to kidney failure or heart rhythm problems.
• Severe infections: Increased risk of life-threatening infections due to low white blood cell counts.

Boxed Warnings

Blincyto has boxed warnings for two serious conditions that may occur during treatment. Healthcare providers monitor patients closely, especially during the first few days of the first and second treatment cycles.

• Cytokine Release Syndrome (CRS): This is a severe systemic inflammatory response that can be life-threatening or fatal. Symptoms may include fever, headache, nausea, low blood pressure, and high liver enzymes.
• Neurological Toxicities: Severe or fatal neurological reactions have occurred. These may include seizures, confusion, disorientation, speech disorders, and loss of consciousness.

Other Serious Warnings

Infections: This medication can increase the risk of serious or fatal bacterial, fungal, and viral infections. Patients are monitored for signs of infection, such as fever, and may receive preventative treatments.

Tumor Lysis Syndrome (TLS): TLS occurs when cancer cells break down rapidly, releasing their contents into the blood. This can lead to kidney failure and heart rhythm problems. Healthcare providers may use intravenous fluids and monitoring to manage this risk.

Liver and Pancreas Toxicity: Treatment may cause inflammation of the pancreas (pancreatitis) or elevations in liver enzymes. Regular blood tests are used to monitor organ function throughout the treatment process.

Infusion Errors: Because the drug is administered as a continuous infusion, errors in preparing the medication or programming the infusion pump can lead to dangerous overdoses or underdoses. It is critical to follow all instructions for the pump and IV bags.

Precautions and Monitoring

Due to the risk of neurological events like seizures or confusion, patients are generally advised to avoid driving or operating heavy machinery while the medication is being administered. Additionally, live virus vaccines should be avoided during and for a period after treatment. Pregnancy should also be avoided, as the medication may cause harm to a developing fetus.

Pregnancy

Blincyto can cause harm to a fetus when administered to a pregnant woman. Based on its mechanism of action, the medication may cause fetal B-cell depletion and affect the development of the immune system. Healthcare providers typically advise against using this medication during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.

Individuals who are able to become pregnant should use effective contraception during treatment and for at least 48 hours after the final dose of Blincyto. If you become pregnant or suspect you are pregnant while receiving this medication, you should notify your healthcare provider immediately.

Breastfeeding

It is not known whether Blincyto passes into human breast milk. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment. Patients should avoid breastfeeding while receiving Blincyto and for at least 48 hours after the last dose. It is important to discuss infant feeding options with a healthcare professional before starting treatment.

Dosage Forms

Blincyto is available in the following form:

• Lyophilized powder for injection: A sterile, preservative-free powder supplied in a single-dose vial for reconstitution and dilution.

Administration Method

This medication is not given as a standard injection. It is prepared for continuous intravenous infusion, which involves a specific preparation process:

• The powder is reconstituted with sterile water.
• The resulting solution is diluted into an infusion bag that contains a specific IV Solution Stabilizer provided by the manufacturer.
• The medication is delivered through an infusion pump to ensure a constant, steady flow into the vein over a designated period.

FDA Approval History

Blincyto first received accelerated approval from the U.S. Food and Drug Administration (FDA) in December 2014. It was initially indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, the FDA has expanded its approved uses based on clinical trial data showing its effectiveness in various stages of the disease.

Approved Indications

The FDA has approved Blincyto for the following patient populations:

• Adults and children with CD19-positive B-cell precursor ALL that has returned (relapsed) or did not respond to initial treatment (refractory).
• Adults and children with B-cell precursor ALL who are in their first or second complete remission but still have minimal residual disease (MRD) greater than or equal to 0.1%.
• Adults and children with CD19-positive Philadelphia chromosome-negative B-cell precursor ALL during the consolidation phase of chemotherapy.

Boxed Warnings

Blincyto carries a boxed warning, which is the most serious type of warning required by the FDA, for the following conditions:

• Cytokine Release Syndrome (CRS): This is a potentially life-threatening systemic inflammatory response. Healthcare providers must monitor patients closely for symptoms such as fever, headache, or low blood pressure.
• Neurological Toxicities: Serious or life-threatening neurological events have occurred in patients. These may include seizures, speech problems, confusion, or loss of balance.

Risk Evaluation and Mitigation Strategy (REMS)

Because of the risks associated with cytokine release syndrome and neurological toxicities, Blincyto is only available through a restricted program called the Blincyto REMS. This program ensures that healthcare professionals who prescribe and dispense the medication are informed about these risks and that the drug is administered in settings equipped to manage severe reactions.

Orphan Drug Designation

Blincyto was granted Orphan Drug designation by the FDA. This status is given to drugs intended to treat rare diseases or conditions, providing incentives to manufacturers to develop treatments for small patient populations.

Factors Influencing Cost

The total price of treatment with Blincyto depends on several variables. Because it is a specialty biologic medication administered as a continuous intravenous infusion, costs are not fixed. Key factors include:

• Treatment Setting: Blincyto treatment often begins in a hospital or clinic and may continue at home with a portable pump. Costs for hospital stays, nursing care, and equipment will affect the total bill.
• Dosage and Duration: The number of cycles prescribed for your specific condition directly impacts the overall cost.
• Insurance Type: Coverage varies between private insurance, Medicare, and Medicaid. Out-of-pocket expenses such as deductibles, copayments, and coinsurance will depend on your specific plan.

Financial Assistance Programs

Many patients do not pay the full list price for Blincyto. Financial support options may be available to help manage the expense:

• Manufacturer Support: The drug manufacturer often provides programs to help eligible patients with commercial insurance reduce their out-of-pocket costs.
• Patient Assistance Programs: These programs may provide the medication at low or no cost to individuals who are uninsured or meet specific financial need criteria.
• Support Services: Specialized coordinators can often help navigate insurance authorizations and identify available financial resources.

It is important to consult with your healthcare provider, hospital billing department, or insurance company to understand the specific costs associated with your treatment plan.